- Home
- DKS vs GMAB Comparison
DKS vs GMAB Comparison
Compare DKS & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DKS
- GMAB
- Stock Information
- Founded
- DKS 1948
- GMAB 1999
- Country
- DKS United States
- GMAB Denmark
- Employees
- DKS N/A
- GMAB N/A
- Industry
- DKS Other Specialty Stores
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- DKS Consumer Discretionary
- GMAB Health Care
- Exchange
- DKS Nasdaq
- GMAB Nasdaq
- Market Cap
- DKS 14.6B
- GMAB 13.2B
- IPO Year
- DKS N/A
- GMAB N/A
- Fundamental
- Price
- DKS $227.52
- GMAB $24.65
- Analyst Decision
- DKS Buy
- GMAB Buy
- Analyst Count
- DKS 19
- GMAB 6
- Target Price
- DKS $234.50
- GMAB $37.60
- AVG Volume (30 Days)
- DKS 1.2M
- GMAB 1.2M
- Earning Date
- DKS 08-28-2025
- GMAB 08-07-2025
- Dividend Yield
- DKS 2.13%
- GMAB N/A
- EPS Growth
- DKS 16.10
- GMAB 77.72
- EPS
- DKS 14.00
- GMAB 21.62
- Revenue
- DKS $13,599,143,000.00
- GMAB $3,646,881,232.00
- Revenue This Year
- DKS $5.01
- GMAB $21.64
- Revenue Next Year
- DKS $3.46
- GMAB $15.57
- P/E Ratio
- DKS $16.26
- GMAB $11.06
- Revenue Growth
- DKS 3.33
- GMAB 32.97
- 52 Week Low
- DKS $166.37
- GMAB $17.24
- 52 Week High
- DKS $254.60
- GMAB $27.94
- Technical
- Relative Strength Index (RSI)
- DKS 62.96
- GMAB 67.82
- Support Level
- DKS $218.50
- GMAB $21.00
- Resistance Level
- DKS $229.39
- GMAB $22.90
- Average True Range (ATR)
- DKS 5.20
- GMAB 0.43
- MACD
- DKS 0.24
- GMAB 0.24
- Stochastic Oscillator
- DKS 90.90
- GMAB 95.31
About DKS Dick's Sporting Goods Inc
Dick's Sporting Goods retails athletic apparel, footwear, and equipment for sports. Dick's operates digital platforms, about 720 stores under its namesake brand (including outlet stores and House of Sport), and about 130 specialty stores under the Golf Galaxy and other nameplates. Dick's carries private-label merchandise and national brands such as Nike, The North Face, Under Armour, Callaway Golf, and TaylorMade. Based in the Pittsburgh area, Dick's was founded in 1948 by the father of current executive chair and controlling shareholder Edward Stack.
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.